Gene, Cell and Tissue

Published by: Kowsar

Evaluation of 40-bp Insertion/Deletion Polymorphism of MDM2 and the Risk of Childhood Acute Lymphoblastic Leukemia

Mohammad Hashemi 1 , 2 , * , Majid Naderi 3 , 4 , Ebrahim Eskandari Nasab 3 , Seyed Shahaboddin Hasani 2 , Simin Sadeghi Bojd 4 and Mohsen Taheri 3
Authors Information
1 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Genetics of Non Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
4 Department of Pediatrics, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • Gene, Cell and Tissue: January 01, 2015, 2 (1); e26974
  • Published Online: January 24, 2015
  • Article Type: Research Article
  • Received: December 14, 2014
  • Accepted: December 14, 2014
  • DOI: 10.17795/gct-26974

To Cite: Hashemi M, Naderi M, Eskandari Nasab E, Hasani S S, Sadeghi Bojd S, et al. Evaluation of 40-bp Insertion/Deletion Polymorphism of MDM2 and the Risk of Childhood Acute Lymphoblastic Leukemia, Gene Cell Tissue. 2015 ; 2(1):e26974. doi: 10.17795/gct-26974.

Copyright © 2015, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Swinney RM, Hsu SC, Hirschman BA, Chen TT, Tomlinson GE. MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia. 2005; 19(11): 1996-8[DOI][PubMed]
  • 2. Canalle R, Burim RV, Tone LG, Takahashi CS. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen. 2004; 43(2): 100-9[DOI][PubMed]
  • 3. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810): 307-10[DOI][PubMed]
  • 4. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3): 323-31[PubMed]
  • 5. Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med. 1997; 3(7): 441-51[PubMed]
  • 6. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev. 2002; 12(1): 53-9[PubMed]
  • 7. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630): 296-9[DOI][PubMed]
  • 8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997; 387(6630): 299-303[DOI][PubMed]
  • 9. Gao J, Kang AJ, Lin S, Dai ZJ, Zhang SQ, Liu D, et al. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls. Ther Clin Risk Manag. 2014; 10: 269-77[DOI][PubMed]
  • 10. Zhuo X, Ren J, Li D, Wu Y, Zhou Q. MDM2 SNP309 variation increases cervical cancer risk among Asians. Tumour Biol. 2014; 35(6): 5331-7[DOI][PubMed]
  • 11. Wang LH, Wang X, Xu WT, Hu YL. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis. Tumour Biol. 2014; 35(4): 3167-70[DOI][PubMed]
  • 12. Dong D, Gao X, Zhu Z, Yu Q, Bian S, Gao Y. A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population. Gene. 2012; 497(1): 66-70[DOI][PubMed]
  • 13. Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer. 2006; 118(5): 1275-8[DOI][PubMed]
  • 14. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006; 240(2): 261-7[DOI][PubMed]
  • 15. Hashemi M, Omrani M, Eskandari-Nasab E, Hasani SS, Mashhadi MA, Taheri M. A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increased the risk of breast cancer in Zahedan, Southeast Iran. Iran Biomed J. 2014; 18(4): 245-9[PubMed]
  • 16. Hasani SS, Hashemi M, Eskandari-Nasab E, Naderi M, Omrani M, Sheybani-Nasab M. A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. Tumour Biol. 2014; 35(1): 219-25[DOI][PubMed]
  • 17. Hashemi M, Ebrahimi M, Amininia S, Naderi M, Eskandari-Nasab E, Taheri M. Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran. Int J Hematol Oncol Stem Cell Res. 2014; 8(4): 39-44
  • 18. Hashemi M, Sheybani-Nasab M, Naderi M, Roodbari F, Taheri M. Association of functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report. Tumour Biol. 2014; 35(10): 10375-9[DOI][PubMed]
  • 19. Pastinen T, Sladek R, Gurd S, Sammak A, Ge B, Lepage P, et al. A survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics. 2004; 16(2): 184-93[DOI][PubMed]
  • 20. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993; 82(9): 2617-23[PubMed]
  • 21. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992; 358(6381): 80-3[DOI][PubMed]
  • 22. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53(10 Suppl): 2231-4[PubMed]
  • 23. Zhuo W, Zhang L, Ling J, Zhu B, Chen Z. MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymphoma. 2012; 53(11): 2245-52[DOI][PubMed]
  • 24. Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, et al. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib. Mol Carcinog. 2014; 53(12): 951-9[DOI][PubMed]
  • 25. Chen J, Zhu B, Chen J, Li Y. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population. DNA Cell Biol. 2013; 32(7): 414-9[DOI][PubMed]
  • 26. Zhang X, Gu L, Li J, Shah N, He J, Yang L, et al. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010; 70(23): 9895-904[DOI][PubMed]
  • 27. Wang W, Du M, Gu D, Zhu L, Chu H, Tong N, et al. MDM2 SNP309 polymorphism is associated with colorectal cancer risk. Sci Rep. 2014; 4: 4851[DOI][PubMed]
  • 28. Zhao Y, Yang X, Hao X, Pan X, Zhao B, Ma J, et al. Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies. Tumour Biol. 2014; 35(8): 7555-60[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments